Stay updated with breaking news from Christopher Posner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STAMFORD, Conn., April 02, 2024 -- Cara Therapeutics, Inc. , a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from...
Stamford-based Cara Therapeutics Inc. (NASDAQ: CARA) is laying off part of its workforce in an effort to reduce operating costs while shifting its primary focus to developing a drug to treat notalgia paresthetica (NP), a neuropathic disorder for which here is no federally approved therapy.
22.01.2024 - – Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ... Seite 1
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all...
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025–